Liu C Y, Fu R, Wang H Q, Li L J, Liu H, Guan J, Wang T, Qi W W, Ruan E B, Qu W, Wang G J, Liu H, Wu Y H, Song J, Xing L M, Shao Z H
Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
Genet Mol Res. 2014 May 30;13(2):4083-8. doi: 10.4238/2014.May.30.3.
Fas/FasL protein expression of bone marrow hematopoietic cells was investigated in severe aplastic anemia (SAA) patients. Fas expression was evaluated in CD34(+), GlycoA(+), CD33(+), and CD14(+) cells labeled with monoclonal antibodies in newly diagnosed and remission SAA patients along with normal controls. FasL expression was evaluated in CD8(+) cells in the same manner. In CD34(+) cells, Fas expression was significantly higher in the newly diagnosed SAA group (46.59 ± 27.60%) than the remission (6.12 ± 3.35%; P < 0.01) and control (8.89 ± 7.28%; P < 0.01) groups. In CD14(+), CD33(+), and GlycoA(+) cells, Fas levels were significantly lower in the newly diagnosed SAA group (29.29 ± 9.23, 46.88 ± 14.30, and 15.15 ± 9.26%, respectively) than in the remission (47.23 ± 31.56, 67.22 ± 34.68, and 43.56 ± 26.85%, respectively; P < 0.05) and normal control (51.25 ± 38.36, 72.06 ± 39.88, 50.38 ± 39.88%, respectively; P < 0.05) groups. FasL expression of CD8(+) cells was significantly higher in the newly diagnosed SAA group (89.53 ± 45.68%) than the remission (56.39 ± 27.94%; P < 0.01) and control (48.63 ± 27.38%; P <0.01) groups. No significant differences were observed between the remission and control groups. FasL expression in CD8(+) T cells was significantly higher in newly diagnosed patients, and CD34(+), CD33(+), CD14(+), and GlycoA(+) cells all showed Fas antigen expression. The Fas/FasL pathway might play an important role in excessive hematopoietic cell apoptosis in SAA bone marrow. Furthermore, CD34(+) cells are likely the main targets of SAA immune injury.
研究了重型再生障碍性贫血（SAA）患者骨髓造血细胞的Fas/FasL蛋白表达。在新诊断和缓解期的SAA患者以及正常对照中，用单克隆抗体标记CD34(+)、GlycoA(+)、CD33(+)和CD14(+)细胞，评估Fas表达。以同样的方式评估CD8(+)细胞中的FasL表达。在CD34(+)细胞中，新诊断的SAA组Fas表达（46.59±27.60%）显著高于缓解期（6.12±3.35%；P<0.01）和对照组（8.89±7.28%；P<0.01）。在CD14(+)、CD33(+)和GlycoA(+)细胞中，新诊断的SAA组Fas水平（分别为29.29±9.23、46.88±14.30和15.15±9.26%）显著低于缓解期（分别为47.23±31.56、67.22±34.68和43.56±26.85%；P<0.05）和正常对照组（分别为51.25±38.36、72.06±39.88、50.38±39.88%；P<0.05）。新诊断的SAA组CD8(+)细胞的FasL表达（89.53±45.68%）显著高于缓解期（56.39±27.94%；P<0.01）和对照组（48.63±27.38%；P<0.01）。缓解期和对照组之间未观察到显著差异。新诊断患者CD8(+)T细胞中的FasL表达显著更高，且CD34(+)、CD33(+)、CD14(+)和GlycoA(+)细胞均显示Fas抗原表达。Fas/FasL途径可能在SAA骨髓中造血细胞过度凋亡中起重要作用。此外，CD34(+)细胞可能是SAA免疫损伤的主要靶点。
